Comparative Assessment of Health Benefits of Praziquantel Treatment of Urogenital Schistosomiasis in Preschool and Primary School-Aged Children

Figure 2

Effect of praziquantel (PZQ) treatment on the levels of urinary markers of schistosome-related morbidity 12 weeks after treatment. (a) Microhaematuria, (b) proteinuria, and (c) albuminuria. The error bars indicate the 95% confidence intervals. The values for pairwise comparisons are from generalized linear mixed models investigating the probability of a child presenting with morbidity marker pre- versus posttreatment adjusted for sex and age group. Significant values are marked with . value determined using the Binomial exact test.

(a)

(b)

(c)